Ide-Cel: Real-World Outcomes for Relapsed Refractory Multiple Myeloma

Opinion
Video

Panelists discuss how ide-cel, a CAR T-cell therapy, demonstrates promising real-world outcomes in patients with relapsed/refractory multiple myeloma, potentially offering a valuable treatment option for this challenging patient population.

CN24_FO_MM_Seg02_Ide-Cel
Current Time 0:00
Duration 10:39
Loaded: 0%
Stream Type LIVE
Remaining Time 10:39
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Recent Videos
    Treatment Selection, Sequencing, and Supportive Care for Brain Metastases in HER2+ mBC
    Treatment Selection, Sequencing, and Supportive Care for Brain Metastases in HER2+ mBC
    Local and Systemic Approaches in Treating Brain Metastases in HER2+ mBC: The Role of Radiation and SRS
    Local and Systemic Approaches in Treating Brain Metastases in HER2+ mBC: The Role of Radiation and SRS
    Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer
    Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer
    Trastuzumab Deruxtecan in HER2+ Gastric Cancer: Insights From DESTINY-Gastric02
    Trastuzumab Deruxtecan in HER2+ Gastric Cancer: Insights From DESTINY-Gastric02
    Deciding Which RP to Utilize
    Deciding Which RP to Utilize
    Making Sense of PARP Inhibitors
    Making Sense of PARP Inhibitors
    Consideration for Other Androgen Receptor Inhibitors
    Consideration for Other Androgen Receptor Inhibitors
    Prostate Cancer in 2025
    Prostate Cancer in 2025
    Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
    Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
    5 experts in this video
    Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL
    Related Content
    Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

    Modakafusp Alfa Exhibits Antitumor Activity, Immune Activation in Myeloma

    Roman Fabbricatore
    March 25th 2025
    Article

    Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

    Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

    Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

    Samantha Shenoy, NP, MSN
    October 14th 2024
    Podcast

    Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

    Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

    Elotuzumab Plus PVd Displays Efficacy in Relapsed/Refractory Multiple Myeloma

    Roman Fabbricatore
    March 21st 2025
    Article

    Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

    James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

    Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

    James R. Berenson, MD, FACP
    September 30th 2024
    Podcast

    James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

    Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

    Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

    Tim Cortese
    March 14th 2025
    Article

    Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.

    Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

    Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

    ONCOLOGY Staff
    March 9th 2025
    Article

    A cancer care team contemplated the methods and reasoning for handling a complex case of heavily pretreated relapsed or refractory multiple myeloma.